Trial Profile
Phase II trial of metadoxine in pediatric fragile X syndrome
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Nov 2017
Price :
$35
*
At a glance
- Drugs Metadoxine (Primary)
- Indications Fragile X syndrome
- Focus Therapeutic Use
- 15 Nov 2017 According to an Arcturus Therapeutics media release, Alcobra merged with Arcturus Therapeutics and the combined company is named as Arcturus Therapeutics
- 20 Feb 2015 New trial record